ANDA 77781, held by Apotex. Galantamine Hydrobromide.
As of Nov 21, 2026, ANDA 77781 (Galantamine Hydrobromide), held by Apotex, was first approved by FDA on Sep 27, 2011, with 8 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 27, 2011 | Original application | Approved | None posted |
| Galantamine HydrobromideEQ 4MG BASE · tablet;oral | Galantamine Hydrobromide | Discontinued |
| Galantamine HydrobromideEQ 8MG BASE · tablet;oral | Galantamine Hydrobromide | Discontinued |
| Galantamine HydrobromideEQ 12MG BASE · tablet;oral | Galantamine Hydrobromide | Discontinued |
| Jun 28, 2023 | Supplement 10Labeling · Standard review | Approved | None posted |
| Mar 8, 2021 | Supplement 8Labeling · Standard review | Approved | None posted |
| Mar 8, 2021 | Supplement 9Labeling · Standard review | Approved | None posted |
| Dec 14, 2017 | Supplement 5Labeling · Standard review | Approved | None posted |
| Mar 29, 2016 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 29, 2016 | Supplement 3Labeling · Standard review | Approved | None posted |
| Mar 29, 2016 | Supplement 4Labeling · Standard review | Approved | None posted |
| Oct 18, 2012 | Supplement 1Labeling · Standard review | Approved | None posted |
| Sep 27, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters